Research programme: anti-fungal vaccines - MiniVax

Drug Profile

Research programme: anti-fungal vaccines - MiniVax

Alternative Names: MVX-504; MVX-507; PCP-Vaccine

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Louisiana State University Health Sciences Center; MiniVax
  • Developer MiniVax
  • Class Fungal vaccines; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cryptococcosis; Pneumocystis pneumonia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumocystis pneumonia(Prevention) in USA (IM)
  • 16 Jul 2016 No recent reports of development identified for research development in Cryptococcosis(Prevention) in USA (IM)
  • 04 Jun 2012 Preclinical trials in Pneumocystis pneumonia (prevention) in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top